Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 147.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 53,590 shares of the company’s stock after acquiring an additional 31,976 shares during the quarter. Sanctuary Advisors LLC owned about 0.05% of Intellia Therapeutics worth $1,101,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares during the last quarter. Eastern Bank acquired a new position in Intellia Therapeutics during the third quarter worth about $41,000. Values First Advisors Inc. purchased a new stake in Intellia Therapeutics during the 3rd quarter valued at about $54,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $12.18 on Friday. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -2.24 and a beta of 1.76. The business has a 50-day moving average of $15.59 and a 200 day moving average of $20.26. Intellia Therapeutics, Inc. has a 12 month low of $11.79 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The company’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.38) EPS. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on NTLA shares. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. William Blair reaffirmed a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. Oppenheimer reduced their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Robert W. Baird dropped their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Wedbush reaffirmed a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average target price of $54.94.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.